Posted by Michael Wonder on 21 Oct 2022
US FDA accepts supplemental new drug application for Camzyos (mavacamten) in symptomatic obstructive hypertrophic cardiomyopathy to reduce the need for septal reduction therapy
21 October 2022 - Application based on results from the Phase 3 VALOR-HCM study.
Bristol Myers Squibb today announced that the US FDA has accepted its supplemental new drug application for Camzyos (mavacamten) for an expanded indication to reduce the need for septal reduction therapy.
